WO2018226521A1 - Compositions and methods for reducing flatulence - Google Patents
Compositions and methods for reducing flatulence Download PDFInfo
- Publication number
- WO2018226521A1 WO2018226521A1 PCT/US2018/035563 US2018035563W WO2018226521A1 WO 2018226521 A1 WO2018226521 A1 WO 2018226521A1 US 2018035563 W US2018035563 W US 2018035563W WO 2018226521 A1 WO2018226521 A1 WO 2018226521A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacillus
- gas
- atcc
- mrsd
- acinetobacter
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 206010016766 flatulence Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 49
- 239000006041 probiotic Substances 0.000 claims abstract description 26
- 235000018291 probiotics Nutrition 0.000 claims abstract description 26
- 230000009467 reduction Effects 0.000 claims abstract description 21
- 230000000968 intestinal effect Effects 0.000 claims abstract description 20
- 230000000529 probiotic effect Effects 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 43
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 30
- 229940054340 bacillus coagulans Drugs 0.000 claims description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 26
- 239000008101 lactose Substances 0.000 claims description 21
- 206010000060 Abdominal distension Diseases 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008121 dextrose Substances 0.000 claims description 17
- 229920001592 potato starch Polymers 0.000 claims description 16
- 235000013406 prebiotics Nutrition 0.000 claims description 16
- 229920001100 Polydextrose Polymers 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 239000001259 polydextrose Substances 0.000 claims description 15
- 235000013856 polydextrose Nutrition 0.000 claims description 15
- 229940035035 polydextrose Drugs 0.000 claims description 15
- 241000193163 Clostridioides difficile Species 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 241000588624 Acinetobacter calcoaceticus Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 208000024330 bloating Diseases 0.000 claims description 12
- 241000589291 Acinetobacter Species 0.000 claims description 11
- 206010012735 Diarrhoea Diseases 0.000 claims description 9
- 206010015137 Eructation Diseases 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- 229920001202 Inulin Polymers 0.000 claims description 7
- 208000027687 belching Diseases 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 241001495172 Bilophila wadsworthia Species 0.000 claims description 6
- 208000005577 Gastroenteritis Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 241000122229 Acinetobacter johnsonii Species 0.000 claims description 5
- 241000193403 Clostridium Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 206010000059 abdominal discomfort Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000006227 byproduct Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- -1 gummies Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 241000283913 Bacillus coagulans DSM 1 = ATCC 7050 Species 0.000 claims description 2
- 240000003550 Eusideroxylon zwageri Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 42
- 244000005700 microbiome Species 0.000 abstract description 6
- 239000007789 gas Substances 0.000 description 85
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 23
- 150000003271 galactooligosaccharides Chemical class 0.000 description 23
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 229960001031 glucose Drugs 0.000 description 15
- 239000013028 medium composition Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000273265 Clostridioides difficile ATCC 9689 = DSM 1296 Species 0.000 description 6
- 241000202985 Methanobrevibacter smithii Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 241001495171 Bilophila Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 241000202987 Methanobrevibacter Species 0.000 description 4
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 241000447858 Bilophila wadsworthia ATCC 49260 Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001307981 Methanobrevibacter smithii ATCC 35061 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000588625 Acinetobacter sp. Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010004142 Bartholinitis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 241000148131 Colibacter Species 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000000434 Melocanna baccifera Nutrition 0.000 description 1
- 241001497770 Melocanna baccifera Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 241000778396 Oncaea media Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 244000096108 cunha Species 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention in general relates to flatulence reduction. More specifically, the present invention relates to a composition containing probiotic bacteria Bacillus coagulans and methods thereof for the reduction of intestinal gas and inhibiting gas producing microorganisms.
- Intestinal gas or flatulence is a . biological process wherein excess gas collects i the digestive system, as a result of swallowing too much air while drinking and eating. Gas also gets accumulated as a result of the normal digestive process due to fermentation of food stuff. The body gets rid of the excess gas by farting (flatulence) or burping (belching). Sometimes, excessive flatulence indicate an underlying health condition such as irritable bowel syndrome, indigestion, constipation, cramps, bloating, diarrhea, coeiiac disease, lactose intolerance, gastroenteritis and giardiasis - an infection of the digestive system caused by microbes.
- Intestinal microbes which include, but not limited to, E. coll, Clostridium, difficile Acinetobacier calcoaceticus, Acmetohacter johmanu, Methanobrevibacter smithii, and Bilophila wadmorthia etc., increase the intestinal gas by fermenting undigested food stuff.
- Acinetobacier calcoaceticus is a non-motile, Gram negative coccobacillus, bacterial species of the genus Acmetohacter. It is catalase positi ve and oxidase negati ve and grows under aerobic conditions and considered to be the part of the normal human intestinal flora.
- Acmetohacter species including Acmetohacter banmannii, Acmetohacter calcoaceticus, and Acinetobacier Iwoffii, are rare in the healthy human gut.
- Acinetobacter johnsonii is usually found in the environment and animals. It can occasionally colonize human skin and cause clinical infections such as catheter-related bloodstream infections or peritonitis associated with peritoneal dialysis (Sabrina Montana et al. 2016, The Genetic Analysis .of an Acinetobacter johnsonii Clinical Strain Evidenced the Presence of Horizontal Genetic Transfer. PLoS One. 2016; 11(8): eOl 61528).
- M. smiihii also scavenges hydrogen from other microbes and use it to produce methane. This interaction may help neighbouring hydrogen-producing bacteria to thrive and extract nutrients from food more efficiently. Thus, tins may contribute to weight gain.
- the presence of both methane and hydrogen on breath testing was associated with increased BMI and percent body fat in humans. Hence, inhibiting the growth/number of M.
- Bilophiia wadswerthia is the third most common anaerobe recovered from clinical material obtained from patients with perforated and gangrenous appendicitis.
- Bilophiia wadsworthia contributes to less than 0.01% of the normal human gastrointestinal microbiota but the increase in the number of this organism was observed in multiple disease conditions.
- Clostridium difficile often called C. difficile or C. diff is anaerobic, motile, ubiquitous, Gram-positive, spore-forming bacterium which causes symptomatic infections such as watery diarrhea, fever, nausea, and abdominal pain. It makes up about 20% of cases of antibiotic-associated diarrhea. Complications may include pseudomembranous colitis, toxic megacolon, perforation of the colon, bloating, or blood in stool and sepsis (Nelson RL et al. 2017, Antibiotic treatment fo Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017 Mar 3;3: CD004610).
- the principle objective of the inventions is to disclose a method for the reduction of intestinal gas using a composition comprising Bacillus coagidans.
- the present invention discloses methods and compositions for the reduction of intestinal gas/flatulence. Specifically the invention discloses a method for reducing flatulence using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856. More specifically, the invention discloses a method for inhibiting the growth of microorganisms that facilitate the production of intestinal gas, using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856.
- [ParaOOlSj Fig 1. shows the illustrative representation of the experimental procedure to evaluate the inhibition of gas production of pathogens by the probiotic strain Bacillus coagulans MTCC 5856.
- the present invention discloses a method for reducing gas formed as a by-product of microbial fermentation, said metho comprising steps of co- culturing the gas producing microbes with a probiotic bacteria Bacillus coagulans, in the presence of media containing carbohydrate source and prebiotic fibres, to bring about the reduction in gas formation.
- the probiotic bacteria Bacillus coagulans per se does not produce substantial gas/flatus when cultured with carbohydrate source and prebiotic fibres.
- the Bacillus coagulans is in the form of spore and/or a vegetative cell.
- the strai of Bacillus coagulans is selected from the group consisting of Bacillus coagulans MTCC 5856, Bacillus coagulans ATCC 31284 and Bacillus coagulans ATCC 7050.
- the gas producing microbes are selected from the list consisting of E. coll, Acinetohacter baumannii, Acinetohacter calcoaceticus, Acinetohacter twoffii, Acinetohacter jolmsonii, Methanobrevibacier smithii, Bilophila wadsworthia, and Clostridium difficile.
- the carbohydrate source and prebiotic fibres are selected form the group consisting of fnieto-oligosaccharide (FOS), Galacto-oligosaccharide (GOS), Lactose, potato starch, Inulin. polydextrose and dextrose.
- FOS fnieto-oligosaccharide
- GOS Galacto-oligosaccharide
- Lactose lactose
- potato starch Inulin. polydextrose and dextrose.
- the present invention discloses a method for inhibiting the growth of gas producing microbes, said method comprising steps of co- culturing the gas producin microbes with a probiotic bacteria Bacillus coagulans, in the presence of media containing carbohydrate source and prebiotic fibre, to bring about the reduction in the viable colonies of gas producing microbes.
- Bacillus coagulans is i the form of spore and/or a vegetative ceil.
- the strain of Bacillus coagulans is selected from the group consisting of Bacillus coagulans MTCC 5856, Bacillus coagulans ATCC 31284 and Bacillus coagulans ATCC 7050.1n another preferred embodiment, the gas producing microbes are selected from the list consisting of E. coii, Acinetohacter baumannii, Acinetohacter cakoacetictis, and Acinetohacter Iwqfftt, Acinetohacter johnsonii, Methanobrevihacter smithii, Bilophila wadsworthia, and Clostridium difficile.
- the carbohydrate source and prebiotic fibres are selected form the grou consisting of fmcto-oligosaecharide (FOS), Galacto-oligosaccharide (GOS), Lactose, potato starch, , Inulin, polydextrose and dextrose.
- the inventio discloses a method of reducing flatus (intestinal gas), formed as a byproduct of bacterial fermentation in mammalian gastrointestinal tract, said method comprising step of administerin an effective dose of a composition containing Bacillus coagulans to bring about the effect of reducing volume of flatus formed.
- the probiotic bacteria Bacillus coagulan per se does not produce substantial flatus when administered individually or in combination with carbohydrate source and prebiotic fibres, to a related embodiment, the Bacillus coagulans is in the form of spore and/or a vegetative cell.
- the strain of Bacillus coaguians is selected from the grou consisting of Bacillus coaguians MTCC 5856, Bacillus coaguians ATCC 31284 and Bacillus coaguians ATCC 7050.
- the reduction of flatus formation brings about reduction in bloating and'' or bloating before it starts, abdominal discomfort and distension, excessive gas pressure and belching, diarrhea, coeliac disease, gastroenteritis in said mammals
- the flatus producing bacteria are selected from the list consisting of E.
- the effective dose of Bacillus coaguians is 1 > 10 6 to lxlO 14 cfu. In another related embodiment, the effective dose of Bacillus coaguians is preferably 2 x ) 9 cfu.
- the composition is formulated with pharmaceutiealiy/hiitraceuticaily acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, ehewa les, candies and eatables.
- the mammal is preferably human.
- the invention discloses a method of reducing the numbers of flatus (intestinal gas) causing bacteria in the mammalian gastrointestinal tract, said method comprising step of administering an effective dose of a composition containing Bacillus coaguians to bring about the effect of reductio in the viable colonies of flatus causing bacteria in mammalian gastrointestinal tract.
- the Bacillus coaguians is in the form of spore and/or a vegetative cell
- the strain of Bacillus coaguians is selected from the grou consisting of Bacillus coaguians MTCC 5856, Bacillus coaguians ATCC 31284 and Bacillus coaguians ATCC 7050.
- the reduction of flatus forming bacteria brings about reduction in bloating and/ or bloating before it starts, abdominal discomfort and distension, excessive gas pressure and belching, diarrhea, coeliac disease, gastroenteritis in said mammals.
- the flatus producing microbes are selected from the list consisting of E.
- the effective dose of Bacillus coaguians is 1 ⁇ 10 ; ' to l lO' 4 cfu.
- the effective dose of Bacillus coaguians is preferably 2> lO cfu.
- the composition is formulated with pharmaceutically/nutraceuticail acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies and eatables.
- the mammal is preferably human.
- MRS De Man, Rogosa and Sharpe
- Microorganisms including Escherichia coli, Acinetobacter calcoaceticus, Acinetobacter johnsomi, Methanobrevibacter smit ii, Clostridium difficile, Bilophila wadswortkia were studied in a co-culture model along with probiotic strain B. coaguians MTCC 5856.
- Escherichia coli, Acinetobacter calcoaceticus and Acinetobacter johnsomi were grown in trypticase soya broth and K coli and Acinetobacter calcoaceticus and Acinetobacter johnsomi were enumerated in Eosin methylene blue agar and trypticase soya agar respectively.
- Methanobrevibacter smithii, Clostridium difficile, Bilophila wadsworihia were grown in Wilfcins Chalgren broth supplemented with 5% fetal calf bovine.
- Overnight grown culture of B ⁇ coaguians MTCC 5856 was inoculated in different sets of test tube containing 10 ml of media (supplemented with different carbon source along with prebiotie fibres) along with Durham tube. Further, each set was inoculated with different pathogens and incubated at 37°C in an anaerobic environment using Anaerobic workstation (Imset, India). After incubation, tubes were observed for visible gas production. For each carbon source and each pathogen, respective controls were taken where one tube had only B.
- coaguians MTCC 5856 and one tube had only pathogenic microbes.
- the third tube was inoculated with both B. coaguians MTCC 5856 and pathogens.
- viable counts of pathogens were estimated on respective selective agar media using a plate count method.
- Table 1-6 shows the results of reduction of gas by B. coagulam MTCC 5856 formed due to the presence of pathogenic microbes E. coti ATCC 8739, Acinetobacter calcoaceticus ATCC 23055, Acinetobacter johnsonii C1MB9871 , Methanobrevibacter smithii DSM-86 , Clostridium difficile ATCC 9689, Btiophila wadsworthia ATCC 49260 using GOS, FOS, Lactose, Starch as substrate
- MRSD is the MRS media devoid of dextrose
- Table 3 Gas production by B. coaguiam MTCC 5856 and Acmetobacler johnsomi NCIMB9871 alone and in combination using GOS, FOS, Lactose, Starch as substrate
- Table 4 Gas production by 2. coagukms MTCC 5856 and Methanobrevibacter smithii DSM-861_alone and in combination using GOS, FOS, Lactose, Starch as substrate
- MRSD is the MRS media devoid of dextrose
- Table 5 Gas production by B. coaguians MTCC 5856 and Clostridium difficile ATCC 9689 alone and in combination using GOS, FOS, Lactose, Starch as substrate
- MRSD is the MRS media devoid of dextrose
- Table 6 Gas production by B. coaguians MTCC 5856 and Bilophila wadmorthia ATCC 49260 alone and hi combination using GOS, FOS, Lactose, Starch as substrate
- MRSD is the MRS media devoid of dextrose
- Tables 7-12 depict the effect of Bacillus coagulans MTCC 5856 on the growth and viable count of flatus producing microbes E. coii ATCC 8739, Acineiobacter calcoaceticus ATCC 23055, Acineiobacter johnsonii NCIMB9871, Methanobrevibacter smith DSM-861, Clostridium difficile ATCC 9689, Bilophila wadsworthia ATCC 49260. fPara i)36]Tab]e 7, Effect of B, coagulans MTCC 5856 oa th ⁇ viable count of E. coii ATCC 8739
- Example 4 Compositions/formulations containing Bacillus coagulans for reducing flatus
- Microcrystailme cellulose Colloidal silicon dioxide, Magnesium stearate
- Microcrystailme cellulose Colloidal silicon dioxide, Magnesium stearate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18812746.8A EP3635092A4 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
AU2018282018A AU2018282018B2 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
JP2019566674A JP6987888B2 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
KR1020197038978A KR102452792B1 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
CA3065314A CA3065314A1 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
NZ759306A NZ759306A (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517314P | 2017-06-09 | 2017-06-09 | |
US62/517,314 | 2017-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018226521A1 true WO2018226521A1 (en) | 2018-12-13 |
Family
ID=64562462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/035563 WO2018226521A1 (en) | 2017-06-09 | 2018-06-01 | Compositions and methods for reducing flatulence |
Country Status (8)
Country | Link |
---|---|
US (1) | US10806760B2 (en) |
EP (1) | EP3635092A4 (en) |
JP (1) | JP6987888B2 (en) |
KR (1) | KR102452792B1 (en) |
AU (1) | AU2018282018B2 (en) |
CA (1) | CA3065314A1 (en) |
NZ (1) | NZ759306A (en) |
WO (1) | WO2018226521A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021028311A1 (en) * | 2019-08-09 | 2021-02-18 | Chr. Hansen A/S | Detection of the inhibition capacity of a first microbial strain on the gas production of a second gas producing microbial strain |
JP2022523600A (en) * | 2019-04-02 | 2022-04-25 | ムハンメド マジード | Methods and compositions for therapeutic management of gluten intolerance |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11202810B2 (en) * | 2019-04-02 | 2021-12-21 | Sami-Sabinsa Group Limited | Stable probiotic composition for the management of lactose intolerance |
EP4025299A4 (en) * | 2019-09-05 | 2023-08-23 | Superbrewed Food, Inc. | Mixotrophic probiotic compositions and uses thereof in the treatment of bloating |
CN115354002B (en) * | 2022-09-20 | 2023-12-19 | 微康益生菌(苏州)股份有限公司 | Bacillus coagulans BC07, application thereof, and bacteriostat, medicine, food and bacteriostasis method thereof |
KR102623909B1 (en) * | 2022-11-09 | 2024-01-12 | (주)진바이오텍 | Microorganism strain having inhibitor for biofilm in animal intestines derived from Escherichia coli |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100535A1 (en) * | 1998-08-07 | 2005-05-12 | Sean Farmer | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US20100215738A1 (en) * | 2009-02-24 | 2010-08-26 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20130273016A1 (en) * | 2010-12-29 | 2013-10-17 | Magali Faure | Fiber and probiotics for reducing intestinal symptoms related to chronic stress |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839993D1 (en) * | 1997-06-03 | 2008-10-23 | Ganeden Biotech Inc | PROBIOTIC MILKY ACID BACTERIUM FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH SIDS |
JP2003513649A (en) * | 1999-11-08 | 2003-04-15 | ガネデン バイオテック, インコーポレイテッド | Inhibition of pathogens by Bacilluscoagulans |
US6849256B1 (en) * | 1999-11-08 | 2005-02-01 | Ganeden Biotech Incorporated | Inhibition of pathogens by probiotic bacteria |
AU2011204886A1 (en) * | 2003-12-05 | 2011-08-11 | Ganeden Biotech, Incorporated | Methods for the Dietary Management of Irritable Bowel Syndrome and Carbohydrate Malabsorption |
US11215607B2 (en) * | 2014-02-18 | 2022-01-04 | Ono Pharmaceutical Co., Ltd. | Biomarker for diagnosis of irritable bowel syndrome |
SG11201706099QA (en) * | 2016-01-07 | 2017-08-30 | Sami Labs Ltd | Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using bacillus coagulans sbc37-01, mtcc 5856 |
-
2018
- 2018-06-01 AU AU2018282018A patent/AU2018282018B2/en active Active
- 2018-06-01 US US15/995,393 patent/US10806760B2/en active Active
- 2018-06-01 CA CA3065314A patent/CA3065314A1/en active Pending
- 2018-06-01 JP JP2019566674A patent/JP6987888B2/en active Active
- 2018-06-01 KR KR1020197038978A patent/KR102452792B1/en active IP Right Grant
- 2018-06-01 WO PCT/US2018/035563 patent/WO2018226521A1/en active Application Filing
- 2018-06-01 NZ NZ759306A patent/NZ759306A/en unknown
- 2018-06-01 EP EP18812746.8A patent/EP3635092A4/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100535A1 (en) * | 1998-08-07 | 2005-05-12 | Sean Farmer | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US20100215738A1 (en) * | 2009-02-24 | 2010-08-26 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20130273016A1 (en) * | 2010-12-29 | 2013-10-17 | Magali Faure | Fiber and probiotics for reducing intestinal symptoms related to chronic stress |
Non-Patent Citations (14)
Title |
---|
"Flatulence", WIKIPEDIA, 20 April 2017 (2017-04-20), XP055557464, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Flatulence&oldid=776337204> [retrieved on 20180803] * |
BAILEY ET AL.: "Effective management of flatulence, American family physician", JOURNAL OF THE AMERICAN ACADEMY OF FAMILY PHYSICIANS, 27 March 2018 (2018-03-27), Retrieved from the Internet <URL:https://mospace.umsystem.edu/xmlui/bitstream/handle/10355/3874/EffectiveManagementFlatulence.pdf?sequence=1&isAllowed=y> |
BARON EJ: "Bilophila wadsworthia: a unique Gram-negative anaerobic rod", ANAEROBE, vol. 3, no. 2-3, April 1997 (1997-04-01), pages 83 - 6 |
DEVKOTA ET AL.: "Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in 1110-/- mice", NATURE, vol. 487, 2012, pages 104 - 108 |
EGLE CEKANAVICIUTE ET AL.: "Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models", PROC NATL ACAD SCI U S A, vol. 114, no. 40, 2017, pages 10713 - 10718, XP055947520, DOI: 10.1073/pnas.1711235114 |
GOTTLIEB, K ET AL.: "Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders", ALIMENT PHARMACOL THER., vol. 43, no. 2, 2015, pages 197 - 212, XP071544008, DOI: 10.1111/apt.13469 |
HUGHES LE: "Cross-reactivity between related sequences found in Acinetobacter sp.,Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosis", J NEUROIMMUNOL, vol. 144, 2003, pages 105 - 115 |
LAWRENCE ET AL.: "Probiotics for recurrent Clostridium difficile disease", JOURNAL OF MEDICAL MICROBIOLOGY, vol. 54, 1 September 2005 (2005-09-01), pages 905 - 906 |
MAJEED ET AL.: "Bacillus coagulans: Probiotic of choice", NUTRACOS, April 2012 (2012-04-01), XP055557465, Retrieved from the Internet <URL:https://www.sabinsa.com/newsroom/articles/bacillus-coagulans-probiotic-of-choice-nutracos-march-april-2012.pdf> [retrieved on 20180803] * |
NELSON RL ET AL.: "Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults", COCHRANE DATABASE SYST REV., vol. 3, 3 March 2017 (2017-03-03), pages CD004610 |
QUIGLEY: "Probiotics in the management of colonic disorders", CURRENT GASTROENTEROLOGY REPORTS, vol. 9, October 2007 (2007-10-01), pages 434 - 440, XP008098423, DOI: 10.1007/s11894-007-0055-7 |
SABRINA MONTANA ET AL.: "The Genetic Analysis of an Acinetobacter johnsonii Clinical Strain Evidenced the Presence of Horizontal Genetic Transfer", PLOS ONE, vol. 11, no. 8, 2016, pages e0161528 |
See also references of EP3635092A4 |
TUOHY ET AL., USING PROBIOTICS AND PREBIOTICS TO IMPROVE GUT HEALTH, vol. 8, 2003, pages 692 - 700 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022523600A (en) * | 2019-04-02 | 2022-04-25 | ムハンメド マジード | Methods and compositions for therapeutic management of gluten intolerance |
JP7390398B2 (en) | 2019-04-02 | 2023-12-01 | サミ-サビンサ グループ リミテッド | Methods and compositions for therapeutic management of gluten intolerance |
WO2021028311A1 (en) * | 2019-08-09 | 2021-02-18 | Chr. Hansen A/S | Detection of the inhibition capacity of a first microbial strain on the gas production of a second gas producing microbial strain |
CN114207142A (en) * | 2019-08-09 | 2022-03-18 | 科·汉森有限公司 | Detection of inhibition ability of first microbial strain on gas production of second gas-producing microbial strain |
Also Published As
Publication number | Publication date |
---|---|
KR102452792B1 (en) | 2022-10-11 |
KR20200014854A (en) | 2020-02-11 |
US10806760B2 (en) | 2020-10-20 |
EP3635092A1 (en) | 2020-04-15 |
JP2020523302A (en) | 2020-08-06 |
EP3635092A4 (en) | 2021-02-24 |
AU2018282018B2 (en) | 2021-11-04 |
CA3065314A1 (en) | 2018-12-13 |
AU2018282018A1 (en) | 2019-12-12 |
JP6987888B2 (en) | 2022-01-05 |
NZ759306A (en) | 2022-07-29 |
US20180353555A1 (en) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018282018B2 (en) | Compositions and methods for reducing flatulence | |
CN111246839B (en) | New use for the treatment of clostridium difficile infection | |
EP1436380B1 (en) | Composition comprising a lactobacillus strain and uses thereof | |
JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
Yang et al. | Effect of synbiotics on intestinal microflora and digestive enzyme activities in rats | |
CN112218646B (en) | Composition and application thereof | |
JP2016533744A (en) | Lactobacillus strains as probiotics | |
EP1102595A2 (en) | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria | |
US11344587B2 (en) | Method of improving urogenital health using probiotic bacteria | |
CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
US20070298018A1 (en) | Novel lactobacillus bulgaricus strain and compositions | |
CN117363530B (en) | Composite probiotics and application thereof in preparation of constipation treatment products | |
EP1719518A1 (en) | Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals | |
CN117917475A (en) | Lactobacillus plantarum P16 for regulating intestinal flora, application, product and method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18812746 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3065314 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019566674 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018282018 Country of ref document: AU Date of ref document: 20180601 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197038978 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018812746 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018812746 Country of ref document: EP Effective date: 20200109 |